Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Lactobacillus crispatus for Obesity-Induced Skin Barrier Dysfunction
NCT07266532Completed
- Sponsor
- Shenzhen People's Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Modality
- Bacterial Strains
- Countries
- 1
01
Overview
Randomised, double-blind trial of lactobacillus crispatus in skin barrier dysfunction (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Transepidermal Water Loss at 1 month. Started Dec 2025; status: completed.
02
Drugs
lactobacillus crispatus
03
Conditions
skin barrier dysfunction
Beyond the preview
Go deeper on NCT07266532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266532.